Abacus Health Products (OTCMKTS:ABAHF) versus Milestone Pharmaceuticals (NASDAQ:MIST) Financial Comparison

Abacus Health Products (OTCMKTS:ABAHF) and Milestone Pharmaceuticals (NASDAQ:MIST) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Abacus Health Products and Milestone Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abacus Health Products	0	0	0	0	0.00
Milestone Pharmaceuticals	1	1	3	1	2.67

Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 553.15%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Abacus Health Products.

Profitability

This table compares Abacus Health Products and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abacus Health Products	N/A	N/A	N/A
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Valuation and Earnings

This table compares Abacus Health Products and Milestone Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abacus Health Products	N/A	N/A	N/A	N/A	N/A
Milestone Pharmaceuticals	$1.55 million	89.16	-$63.06 million	($0.68)	-1.63

Abacus Health Products has higher earnings, but lower revenue than Milestone Pharmaceuticals.

Summary

Milestone Pharmaceuticals beats Abacus Health Products on 7 of the 9 factors compared between the two stocks.

About Abacus Health Products

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.